Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details Narrative)

v3.23.3
Commitments and Contingencies (Details Narrative)
€ in Millions
 1 Months Ended 12 Months Ended
Apr. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
EUR (€)
Apr. 30, 2023
USD ($)
Mar. 31, 2023
USD ($)
Jan. 31, 2019
USD ($)
Jul. 31, 2012
USD ($)
Loss Contingencies [Line Items]                  
Payment to acquire in process research and development     $ 443,250 $ 810,227          
Discovery Collaboration Agreements [Member] | XOMA [Member]                  
Loss Contingencies [Line Items]                  
Milestone payment                 $ 3,800,000
Discovery Collaboration Agreements [Member] | XOMA [Member] | In Process Research and Development [Member]                  
Loss Contingencies [Line Items]                  
License fee $ 500,000                
License fees     $ 0            
Cellca Agreement [Member]                  
Loss Contingencies [Line Items]                  
Description of milestone payments     The Company is obligated to make milestone payments to Cellca totaling up to $0.7 million upon the achievement of certain development and approval milestones if the Buy-Out Option is not exercised.            
Cellca Agreement [Member] | Maximum [Member]                  
Loss Contingencies [Line Items]                  
Milestone payment               $ 700,000  
The Cellca Agreement [Member]                  
Loss Contingencies [Line Items]                  
Milestone payment     $ 600,000            
The Cellca Agreement [Member] | Maximum [Member]                  
Loss Contingencies [Line Items]                  
Payment for annual license fee obligation     600,000            
The Cellca Agreement [Member] | Minimum [Member]                  
Loss Contingencies [Line Items]                  
Payment for annual license fee obligation     100,000            
The Cellca Agreement [Member] | In Process Research and Development [Member]                  
Loss Contingencies [Line Items]                  
License fees     0            
Commercial product license fee payment obligation $ 100,000                
The Brink Agreement [Member]                  
Loss Contingencies [Line Items]                  
Commercial product license fee payment obligation     100,000            
Payment of annual license fee           $ 12,000      
The Brink Agreement [Member] | In Process Research and Development [Member]                  
Loss Contingencies [Line Items]                  
License fee     12,000 200,000          
Commercial product license fee payment obligation     100,000            
InvivoGen Agreement [Member]                  
Loss Contingencies [Line Items]                  
License fees     0            
Payment for annual license fee obligation     100,000   € 0.1        
InvivoGen Agreement [Member] | In Process Research and Development [Member]                  
Loss Contingencies [Line Items]                  
License fees     100,000            
ProteoNic Agreement [Member]                  
Loss Contingencies [Line Items]                  
Milestone payment     1,300,000   € 1.2        
License fees     0            
ProteoNic Agreement [Member] | In Process Research and Development [Member]                  
Loss Contingencies [Line Items]                  
License fees   $ 24,600 24,600            
Navigo Agreement [Member] | Navigo Proteins GmbH [Member] | Technology Service [Member]                  
Loss Contingencies [Line Items]                  
Milestone payment     $ 300,000       $ 1,000,000.0    
Payment to acquire in process research and development       $ 100,000